KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Payables (2016 - 2025)

Gilead Sciences' Payables history spans 17 years, with the latest figure at $715.0 million for Q4 2025.

  • For Q4 2025, Payables fell 14.17% year-over-year to $715.0 million; the TTM value through Dec 2025 reached $715.0 million, down 14.17%, while the annual FY2025 figure was $715.0 million, 14.17% down from the prior year.
  • Payables reached $715.0 million in Q4 2025 per GILD's latest filing, down from $808.0 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $905.0 million in Q4 2022 to a low of $537.0 million in Q2 2024.
  • Average Payables over 5 years is $662.8 million, with a median of $618.0 million recorded in 2022.
  • Peak YoY movement for Payables: tumbled 83.74% in 2021, then surged 54.1% in 2024.
  • A 5-year view of Payables shows it stood at $705.0 million in 2021, then increased by 28.37% to $905.0 million in 2022, then tumbled by 39.23% to $550.0 million in 2023, then skyrocketed by 51.45% to $833.0 million in 2024, then dropped by 14.17% to $715.0 million in 2025.
  • Per Business Quant, the three most recent readings for GILD's Payables are $715.0 million (Q4 2025), $808.0 million (Q3 2025), and $582.0 million (Q2 2025).